CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Inclusion Criteria:

• Male and female subjects with CD30+ Hodgkin lymphoma and Non-Hodgkin lymphomarelapsing after autologous stem-cell transplantation (ASCT), or refractory to 2multidrug regimens and/or anti-CD30 antibody treatment.

• Newly diagnosed CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma patients who areunable to receive or complete standard chemotherapy.

• Karnofsky or Lansky score greater than 60%.

• Expected survival>12 weeks.

• Creatinine<2.5mg/dl.

• ALT (alanine aminotransferase)/AST (aspartate aminotransferase)<3 fold normal.

• Bilirubin<2.5mg/dl.

• Pulse oximetry of >90% on room air.

• Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% ofexpected corrected for hemoglobin.

• Available autologous T cells with 10% or more expression of CD30 CAR determined byflow-cytometry.

• Patients or legal guardians must sign an informed consent indicating that they areaware this is a research study and have been told of its possible benefits and toxicside effects. Patients or their guardians will be given a copy of the consent form.

Exclusion Criteria:

• Active infection such as hepatitis B or C.

• Receive anti-CD30 antibody-based therapy within recent 6 weeks.

• Current use of systemic corticosteroids.

• Pregnant or lactating.

• Confirmed tumor in pulmonary and archenteric tissues.